Nitrous Oxide- Suicidal Ideation
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Charles R Conway, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Severity and number of adverse events in both nitrous oxide and placebo groupsThroughout study duration (approximately 60 days)
Safety and tolerability of inhaled nitrous oxide will be measured by collecting adverse events in both groups at each study visit throughout the study.
- Differential change in suicidal ideationBaseline to Day 7, approximately 7 days (following the inpatient period inhalation sessions)
Participants receiving inpatient treatment as usual plus nitrous oxide compared to participants receiving inpatient treatment as usual plus placebo as measured by scores on the 19-item Scale for Suicidal Ideation (SSI; total score range is 0 to 38, higher scores indicate greater suicidal ideation).
- Identification of pre-treatment key clinical correlates of anti-suicidal response to nitrous oxideChange of scores on the SSI for the approximate 7 days of inpatient period
Correlations of change in Scale for Suicidal Ideation score (SSI; total score range is 0 to 38, higher scores indicate greater suicidal ideation) at end of inpatient period with: 1) presence of family history of alcohol dependence; 2) a personal/family history of suicide attempt or a family history of suicide.